TrianglePUBLICATIONS · 39284383
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2024 Nov
- First author
- Van Gorp T
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Van Gorp T
- type
- Author
- name
- Cibula D
- type
- Author
- name
- Lv W
- type
- Author
- name
- Backes F
- type
- Author
- name
- Ortaç F
- type
- Author
- name
- Hasegawa K
- type
- Author
- name
- Lindemann K
- type
- Author
- name
- Savarese A
- type
- Author
- name
- Laenen A
- type
- Author
- name
- Kim YM
- type
- Author
- name
- Bodnar L
- type
- Author
- name
- Barretina-Ginesta MP
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Van Gorp T
- type
- Author
- name
- Cibula D
- type
- Author
- name
- Lv W
- type
- Author
- name
- Backes F
- type
- Author
- name
- Ortaç F
- type
- Author
- name
- Hasegawa K
- type
- Author
- name
- Lindemann K
- type
- Author
- name
- Savarese A
- type
- Author
- name
- Laenen A
- type
- Author
- name
- Kim YM
- type
- Author
- name
- Bodnar L
- type
- Author
- name
- Barretina-Ginesta MP
- type
- Author
- bibliography ids
- nci-bib-5b994e00f26ac75dcae4cc96
- book metadata
- content sha256
- 1b6d6b4052cca93f667ef327b6725bcb2f6d16697ab6aae41c3066b853d9a840
- document type
- citation
- dois
- 10.1016/j.annonc.2024.08.2242
- electronic publication date
- display
- 2024 Sep 14
- precision
- day
- year
- 2024
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:39284383
- immutable id
- pubmed:39284383@1b6d6b4052cca93f667ef327b6725bcb2f6d16697ab6aae41c3066b853d9a840
- journal
- abbreviation
- Ann Oncol
- issn electronic
- 1569-8041
- issn print
- 0923-7534
- issue
- 11
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 968-980
- volume
- 35
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 39284383
- provenance
- batch id
- 3e43afde6f26fc8df6da
- provider
- NCBI PubMed ESummary
- record sha256
- 264a94cb21658e90360b4aa18184385dae38825bf45d47033b2c2c3f2174bbc7
- response sha256
- fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
- retrieved at
- 2026-09-09T23:48:21.145285+00:00
- publication date
- display
- 2024 Nov
- precision
- month
- year
- 2024
- publication types
- Journal Article
- Clinical Trial, Phase III
- Randomized Controlled Trial
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.
Preserved source evidence · Not medical advice